|

货币单位:美元(USD)

Decibel Therapeutics, Inc. (dbtx)

实时(?):

盘后(?):

读取中...

-- (--%)

开盘价:--	最高价:--	最低价:--	52周最高价:--	52周最低价:--
成交量:--	平均成交量:--	市值:--	市盈率:--	预期市盈率:--
每股收益:--	贝塔系数:--	股息:--	收益率:--	总股本:--

提示:交易结束

Robert E. Landry	Robert E. Landry's current job(s) include serving as the Chief Financial Officer at Checkmate Pharmaceuticals, Inc. since 2022 and as the Chief Financial Officer at Decibel Therapeutics, Inc. since 2023. Mr. Landry's former job(s) include serving as the Director-Pharmaceutical Marketing & Sales at Wyeth Australia Pty Ltd. from 2006 to 2007, as the Treasurer & Principal Corporate Officer at Wyeth LLC from 2007 to 2009, as the Treasurer & Senior Vice President at Pfizer Inc. from 2012 to 2013, as the Chief Financial Officer at Wyeth New Zealand from 2004 to 2006, and as the Chief Financial Officer & Executive VP-Finance at Regeneron Pharmaceuticals, Inc. from 2019 to 2024. Mr. Landry obtained his undergraduate degree from the University of Notre Dame in 1986.

Robert E. Landry

Robert E. Landry's current job(s) include serving as the Chief Financial Officer at Checkmate Pharmaceuticals, Inc. since 2022 and as the Chief Financial Officer at Decibel Therapeutics, Inc. since 2023. Mr. Landry's former job(s) include serving as the Director-Pharmaceutical Marketing & Sales at Wyeth Australia Pty Ltd. from 2006 to 2007, as the Treasurer & Principal Corporate Officer at Wyeth LLC from 2007 to 2009, as the Treasurer & Senior Vice President at Pfizer Inc. from 2012 to 2013, as the Chief Financial Officer at Wyeth New Zealand from 2004 to 2006, and as the Chief Financial Officer & Executive VP-Finance at Regeneron Pharmaceuticals, Inc. from 2019 to 2024. Mr. Landry obtained his undergraduate degree from the University of Notre Dame in 1986.